CoChat
Cited by 186

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer

Open access
Atchley, William T., Alvarez, Carolina, Saxena-Beem, Shruti, Schwartz, Todd A., Ishizawar, Rumey C., Patel, Kunal P., Rivera, M. Patricia · 2021 · Chest

Abstract

BACKGROUND Immune checkpoint inhibitors (ICI) are standard treatments for advanced non-small cell lung cancer and have expanded use in small cell lung cancer. While generally better tolerated than traditional chemotherapy, immune-related adverse events, such as immune checkpoint inhibitor-related pneumonitis (ICI-P), remain poorly understood toxicities that limit ICI treatment and can result in considerable morbidity. In this retrospective case-control study, we assessed a lung cancer cohort to identify ICI-P risk factors. RESEARCH QUESTION What are the risk factors, clinical presentations, radiographic findings, and outcomes for ICI-P in a real-world lung cancer cohort? Do chronic pulmonary diseases confer increased risk for ICI-P? STUDY DESIGN AND METHODS Medical records from lung cancer patients receiving nivolumab, pembrolizumab, or combination ipilimumab and nivolumab at six centers in North Carolina were reviewed (1/2004 - 7/2017). ICI-P cases and controls were characterized and logistic regression was utilized to assess for ICI-P risk factors. RESULTS 315 lung cancer patients who predominantly received nivolumab (76.5%) or pembrolizumab (22%) were included. The incidence of ICI-P was 9.5% with a median time to diagnosis of 52.5 days. The majority of ICI-P cases were high severity, and eight patients (27%) died with ongoing ICI-P treatment. Development of ICI-P was independently associated with the presence of baseline fibrosis on chest computed tomography (aOR 6.61; 95% CI 2.48 - 17.7), a composite measure of obstructive lung disease (aOR 2.79; 95% CI 1.07 - 7.29), and treatment with pembrolizumab (aOR 2.57, 95% CI 1.08 - 6.11). INTERPRETATION In this cohort, ICI-P was more common and severe than previously reported and carried an unexpectedly high mortality rate. Risk for ICI-P appears independently associated with several chronic pulmonary diseases, which may account for the higher incidence of ICI-P in lung cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chest.2021.02.032

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Atchley, W. T., Alvarez, C., Saxena-Beem, S., Schwartz, T. A., Ishizawar, R. C., Patel, K. P., & Rivera, M. P.
Venue
Chest
Publisher
Elsevier BV
Published
2021-08
Volume
160
Issue
2
Pages
731-742
ISSN
0012-3692 (ISSN-L)
OpenAlex
W3132509156
Cited by
186
References
13
FWCI
7.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer. https://app.cochat.ai/papers/10.1016/j.chest.2021.02.032
The paper
Atchley, W. T., Alvarez, C., Saxena-Beem, S., Schwartz, T. A., Ishizawar, R. C., Patel, K. P., & Rivera, M. P. (2021). Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer. Chest. https://doi.org/10.1016/j.chest.2021.02.032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.